(Q41668753)
Statements
1 reference
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (English)
1 reference
Roy M Fleischmann
1 reference
Nemanja S Damjanov
1 reference
Alan J Kivitz
1 reference
Anna Legedza
1 reference
Thomas Hoock
1 reference
Nils Kinnman
1 reference
1 February 2015
1 reference
1 reference
67
1 reference
2
1 reference
334-343
1 reference
Identifiers
1 reference
1 reference